Prima Biomed, through its subsidiaries, is engaged in the research and commercialization of licensed medical biotechnology. The Company develops anti-cancer therapeutics based on immunotherapy. The Company's products include CVac™ which is an ovarian cancer vaccine; and cancer antibody antigen Cripto-1 which is a protein found in high levels on the surface of many different kinds of cancer cells and is also found in the blood stream of cancer patients. The Company is also developing a technology enabling oral administration of vaccines that are injected.
Data provided by Mergent, Inc.